Cardiac Rehabilitation Outcome Following Percutaneous Coronary Intervention Compared to Cardiac Surgery
Abstract:To examine differences in objective and subjective outcomes in outpatients undergoing percutaneous coronary intervention (PCI) performed for acute myocardial infarction versus cardiac surgery (CS) following a phase II cardiac rehabilitation (CR). Longitudinal observational study of 437 consecutive cardiac outpatients after 8 weeks of phase II CR. Patients were divided into the PCI group (n = 281) and CS group (n = 156). Handgrip and knee extensor muscle strength, peak oxygen uptake (VO2), upper- and lower-body self-efficacy for physical activity (SEPA), and physical component summary (PCS) and mental component summary (MCS) scores as assessed by Short Form-36 were measured at 1 and 3 months after PCI or CS. All outcomes increased significantly between months 1 and 3 in both groups. However, increases were greater in the CS versus PCI group in handgrip strength (+12.3 % vs. +8.1%, P > 0.01), knee extensor muscle strength (+19.3% vs. +17.5%, P = 0.008), peak VO2 (+20.9% vs. +16.9%, P > 0.01), upper-body SEPA (+27.7% vs. +9.2%, P = 0.001), and PCS score (+6.5% vs. +4.1%, P = 0.001). Although this relatively short-term phase II CR increased all outcomes for both groups, outcomes showed the recovery process was different between the PCI and CS groups, slightly favoring CS patients. Furthermore, patents in the field of CR are presented.
Keywords: Cardiac rehabilitation; Outcomes at T1; Statistical Analysis; bypass grafting; cardiac surgery; cardiopulmonary exercise testing; health-related quality of life; muscle strength; percutaneous coronary intervention; self-efficacy for physical activity
Document Type: Research Article
Publication date: 2011-05-01
- Recent Patents on Cardiovascular Drug Discovery publishes review articles on recent patents in the field of cardiovascular drug discovery e.g. novel bioactive compounds, analogs & targets. A selection of important and recent patents on cardiovascular drug discovery is also included in the journal. The journal is essential reading for all researchers involved in cardiovascular drug design and discovery.